Menu
Search
|

Menu

Close
X

Cara Therapeutics Inc CARA.OQ (NASDAQ Stock Exchange Global Market)

13.81 USD
-0.67 (-4.63%)
As of Feb 20
chart
Previous Close 14.48
Open 14.48
Volume 188,206
3m Avg Volume 278,791
Today’s High 14.61
Today’s Low 13.71
52 Week High 28.49
52 Week Low 11.12
Shares Outstanding (mil) 32.61
Market Capitalization (mil) 472.17
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY17
1
FY16
0
FY15
4
EPS (USD)
FY17
-1.484
FY16
-2.100
FY15
-0.991
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
35.76
Price to Sales (TTM)
vs sector
518.30
8.59
Price to Book (MRQ)
vs sector
4.77
5.23
Price to Cash Flow (TTM)
vs sector
--
26.13
Total Debt to Equity (MRQ)
vs sector
1.72
15.32
LT Debt to Equity (MRQ)
vs sector
1.72
11.95
Return on Investment (TTM)
vs sector
-75.73
13.59
Return on Equity (TTM)
vs sector
-77.16
15.20

EXECUTIVE LEADERSHIP

Derek Chalmers
President, Chief Executive Officer, Director, Since
Salary: $511,000.00
Bonus: $204,400.00
Mani Mohindru
Chief Financial Officer, Chief Strategy Officer, Since 2017
Salary: --
Bonus: --
Michael Lewis
Chief Scientific Officer, Since 2016
Salary: --
Bonus: --
Frederique Menzaghi
Vice President, Research & Development, Since
Salary: $357,000.00
Bonus: $168,682.00
Joseph Stauffer
Chief Medical Officer, Since 2014
Salary: $414,000.00
Bonus: $223,560.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

4 Stamford Plz
STAMFORD   CT   06902-3834

Phone: +1203.4063700

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.

SPONSORED STORIES